Novel carcinoembryonic-antigen-(CEA)-specific pretargeting system to assess tumor cell viability after irradiation of colorectal cancer cells

Strahlentherapie und Onkologie

Volumn 187, Issue 2, 2011, Pages 120-126

  Meiler, Birgit ^a,c   Rave Fränck, Margarete ^a   Breunig, Christian ^b   Schirmer, Markus ^a   Baehre, Manfred ^c   Nadrowitz, Roger ^b   Liersch, Torsten ^a   Meller, Johannes ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Bispecific antibody; Carcinoembryonic antigen; Colorectal cancer; Irradiation; Pretargeting

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; HAPTEN; INDIUM CHLORIDE IMP 288 PEPTIDE IN 111; INDIUM CHLORIDE IN 111; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TF2 I 131; RNA; TRACER; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; DIAGNOSTIC AGENT; DOTA TYROSYL LYSYL(HISTAMINYL SUCCINYL GLYCYL) GLUTAMYL LYSYL(HISTAMINYL SUCCINYL GLYCYL)AMIDE; DOTA-TYROSYL-LYSYL(HISTAMINYL-SUCCINYL-GLYCYL)-GLUTAMYL-LYSYL(HISTAMINYL-SUCCINY L-GLYCYL)AMIDE; OLIGOPEPTIDE; SINGLE HETEROCYCLIC RINGS; TUMOR MARKER;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; GENE EXPRESSION; HUMAN; HUMAN CELL; IRRADIATION; ISOTOPE LABELING; PHOTON; TREATMENT RESPONSE; ADJUVANT THERAPY; BLOOD; CANCER STAGING; CELL DIVISION; CELL SURVIVAL; COLORECTAL TUMOR; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IN VITRO STUDY; MEGAVOLTAGE RADIOTHERAPY; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIATION EXPOSURE;

ANTIBODIES, BISPECIFIC; APOPTOSIS; CARCINOEMBRYONIC ANTIGEN; CELL DIVISION; CELL SURVIVAL; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, HIGH-ENERGY; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 79954523205     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2191-5     Document Type: Article

References (45)

1. Barbaro B, Fiorucci C, Tebala C, et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 2009;250:730-9.
2. Calcagno AM, Chewning KJ, Wu CP, et al. Plasma membrane calcium ATPase (PMCA4): a housekeeper for RT-PCR relative quantification of polytopic membrane proteins. BMC Mol Biol 2006;7:29.
3. Calvo FA, Domper M, Matute R, et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004;58:528-35. (Pubitemid 38142480)
4. Chen CC, Lee RC, Lin JK, et al. How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis Colon Rectum 2005;48:722-8.
5. Cicinnati VR, Shen Q, Sotiropoulos GC, et al. Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR. BMC Cancer 2008;8:350.
6. Fantini J, Rognoni JB, Culouscou JM, et al. Induction of polarized apical expression and vectorial release of carcinoembryonic antigen (CEA) during the process of differentiation of HT29-D4 cells. J Cell Physiol 1989;141:126-34. (Pubitemid 19243619)
7. Furuta M, Hasegawa M, Hayakawa K, et al. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med 1997;24:435-8. (Pubitemid 27183049)
8. Goldenberg DM, Chatal JF, Barbet J, et al. Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Update Cancer Ther 2007;2:19-31. (Pubitemid 46970909)
9. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23: 338-51. (Pubitemid 41656973)
10. Guerra L, Niespolo R, Di Pisa G, et al. Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdom Imaging 2009 Dec 22 (Epub ahead of print); DOI: 10.1007/s00261-009-9594-8
11. Hicks RJ, Ware RE, Lau EW. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging 2006;6:S52-62.
12. Higashi T, Fisher SJ, Brown RS, et al. Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: preclinical PET studies. J Nucl Med 2000;41:2026-35. (Pubitemid 32038692)
13. Hoffer PB, Lathrop K, Bekerman C, et al. Use of 131-I-CEA antibody as a tumor scanning agent. J Nucl Med 1974;15:323-7.
14. Janssen MH OM, van Stiphout RG, Buijsen J, et al. Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. Radiother Oncol 2010;94:151-55.
15. Karacay H, Sharkey RM, Gold DV, et al. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009;50:2008-16.
16. Lahaye MJ, Engelen SM, Kessels AG, et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 2008;246:804-11.
17. Larbouret C, Robert B, Linard C, et al. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. Int J Radiat Oncol Biol Phys 2007;69:1231-7. (Pubitemid 47625870)
18. Liersch T, Langer C, Jakob C, et al. [Preoperative diagnostic procedures in locally advanced rectal carcinoma (>or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?]. Chirurg 2003;74:224-34. (Pubitemid 38264813)
19. Liersch T, Meller J, Bittrich M, et al. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007;14:2577-90. (Pubitemid 47389553)
20. Liersch T, Meller J, Kulle B, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763-70. (Pubitemid 46190272)
21. Liersch T, Rothe H, Ghadimi BM, et al. [Individualizing treatment for locally advanced rectal cancer]. Chirurg 2009;80:281-93.
22. Marquardt F, Rödel F, Capalbo G, et al. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol 2009;185:371-8.
23. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243:132-9
24. McBride WJ, Zanzonico P, Sharkey RM, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med 2006;47:1678-88. (Pubitemid 47545036)
25. Meller B, Deisting W, Wenzel BE, et al. Increased radioiodine uptake of thyroid cell cultures after external irradiation. Strahlenther Onkol 2006;182:30-6. (Pubitemid 43069833)
26. Ohira H, Kubota K, Ohuchi N, et al. Comparison of intratumoral distribution of 99mTc-MIBI and deoxyglucose in mouse breast cancer models. J Nucl Med 2000;41:1561-8.
27. Park JW, Lim SB, Kim DY, et al. Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and surgery. Int J Radiat Oncol Biol Phys 2009;74:810-7.
28. Paskeviciute B, Bolling T, Brinkmann M, et al. Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer. Strahlenther Onkol 2009;185:260-5.
29. Pelosi E, Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 2007;33:1-6. (Pubitemid 46156622)
30. Rades D, Wolff C, Nadrowitz R, et al. Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy. Int J Radiat Oncol Biol Phys 2009;75:1226-31.
31. Riemann B, Konemann S, Popping D, et al. Early effects of irradiation on [(123)I]-IMT and [(18)F]-FDG uptake in rat C6 glioma cells. Strahlenther Onkol 2004;180:434-41. (Pubitemid 39207382)
32. Rödel C, Arnold D, Hipp M, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008;70:1081-6. (Pubitemid 351296110)
33. Rödel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098-104. (Pubitemid 46613485)
34. Rödel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007;25:110-7. (Pubitemid 350003058)
35. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96. (Pubitemid 46211512)
36. Rödel C, Sauer R, Fietkau R. [The role of magnetic resonance imaging to select patients for preoperative treatment in rectal cancer]. Strahlenther Onkol 2009;185:488-92.
37. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A 2006;103:6841-6.
38. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
39. Sauer R, Fietkau R, Wittekind C, et al. Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). Strahlenther Onkol 2001;177:173-81. (Pubitemid 32303510)
40. Sharkey RM, McBride WJ, Karacay H, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 2003;63:354-63. (Pubitemid 36152493)
41. Tan E, Gouvas N, Nicholls RJ, et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009;18:15-24.
42. Weiss C, Arnold D, Dellas K, et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010;78:472-8.
43. Wolff HA, Gaedcke J, Jung K, et al. High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer. Strahlenther Onkol 2010;186:30-5.
44. Yamamoto T, Nishizawa S, Maruyama I, et al. Acute effects of stereotactic radiosurgery on the kinetics of glucose metabolism in metastatic brain tumors: FDG PET study. Ann Nucl Med 2001;15:103-9. (Pubitemid 32521919)
45. Yoon SM, Kim DY, Kim TH, et al. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2007;69:1167-72. (Pubitemid 47625840)